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Polish Society of Clinical Oncology 
position statement on the urgent need  
of introduction of national standards  
for utilization of biologic drugs  
ABSTRACT
Biosimilar anti-cancer monoclonal antibodies will be introduced into clinical practice in 2018. The advent of 
anti-cancer biosimilars may lead to reduction of the global costs of cancer treatment, diminish the current limita- 
tions related to biological drugs and improve the optimization of cancer therapy. However, one has to realize 
that biosimilar drugs are not generics, and cancer treatment based on biological (biosimilar) drugs should follow 
stringent rules. One of the most important general rules is the prohibition of automatic substitution of biological 
drugs without clinical indications. In the face of introduction of biosimilars, the majority of EU countries, but not 
Poland, has generated national standards for the utilization of biologic drugs, along with lists of drugs which can 
undergo automatic substitution. Lack of such regulations in Poland may complicate effective and safe utilization 
of anti-cancer biological agents in the era of biosimilars.
Key words: biosimilar drugs, monoclonal antibodies, substitution, Polish Society of Clinical Oncology
Oncol Clin Pract 2017; 13, 6: 259–263
Introduction
Significant advances in systemic cancer therapy 
have been made in the past two decades due to better 
understanding of tumour biology and the determin-
ing of mechanisms underlying cancer development 
and progression. According to this, molecular targets 
have been defined, which have become the basis for 
the development of so-called targeted therapies. The 
majority of the first targeted therapies introduced 
into clinical practice in oncology were monoclonal 
antibodies, designed to bind and inactivate membrane 
receptors or their ligands. Monoclonal antibodies are 
among the most complex forms of biological drugs, 
a fact which is related both to the size of the molecule 
and its extremely complex spatial structure. The spa-
tial structure of monoclonal antibodies results from 
post-translational processing of protein chains, which 
is necessary to obtain adequate antibody conformation, 
which in turn is crucial for achieving expected biological 
properties of a drug (affinity, specificity, immunogenic-
ity, and half-life). 
Numerous biological drugs introduced into clinical 
practice have significantly improved the prognosis of 
cancer patients and have represented a breakthrough in 
the treatment of many malignancies, e.g. trastuzumab, 
rituximab, cetuximab, and panitumumab, as well as 
anti-CTLA4 and anti-PD1 or anti-PDL1 antibodies.
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Potential advantages of biosimilar 
medicines
Currently the costs of biological drugs account for 
approx. 20% of all pharmacotherapy expenditure in de-
veloped countries and are largely responsible for a need to 
continuously increase resources dedicated to oncological 
treatment. Expiring patent terms for particular biological 
drugs create an opportunity for the emergence of biosimi-
lars that could potentially reduce costs and increase the 
availability of targeted biological therapies. In countries 
with considerable economic constraints, like Poland, 
the availability of biological drugs in therapeutic drug 
programs does not automatically mean the possibility 
of their potential use in accordance with international 
recommendations. The current reimbursement system 
in Poland does not cover the financing of many innova-
tive medicines in all registered indications. The advent of 
biosimilars should translate in a very short period of time 
into significant price reductions and inclusion of biologi-
cal drugs into the chemotherapy catalogue or therapeutic 
drug programs, which will enable these therapies to be 
used according to current medical knowledge and without 
administrative limitations. Recently registered biosimilars 
have been carefully evaluated in clinical trials, and there is 
no doubt that the effectiveness of the majority of them is 
comparable to the original counterparts. It should also be 
highlighted that the process of registration of biosimilars 
in specific indications of the original drug is to a large ex-
tent based on extrapolation of relatively limited data from 
clinical studies on biosimilar efficacy and safety in the 
context of the whole indication spectrum of the original 
drug. However, this procedure is accepted by regulatory 
agencies and poses a necessary facilitation to reduce the 
costs of research and development of biosimilars, which 
should be significantly lower than for original medicines. 
Differences between biosimilar  
and generics
For most oncology drugs, being simple chemical 
compounds (chemotherapeutics, hormone drugs, and 
small-molecule kinase inhibitors), the expiration of pat-
ent protection has been associated with the immediate 
emergence of generic drugs. This has naturally led in 
the short term to a significant reduction in the price of 
original drugs and improved availability of relatively 
new methods of systemic treatment. In general, the 
manufacturing of generic drugs, being identical copies 
of original ones, is relatively simple because this is based 
on synthesis of simple molecules with low molecular 
weight. Introduction of a generic drug into the market 
requires demonstrating the same composition, form, 
bioavailability, and pharmacological properties as the 
original drug.
In contrast to generics, the production of biosimilars 
represents a huge challenge. The manufacturing process 
of biological drugs with the use of living organisms 
(genetically modified cells) is extremely complicated. 
The final product is a protein that gains its biological 
functions due to its specific spatial structure. Protein 
conformation is determined not only by the specific 
amino acid sequence of the polypeptide chains, but also 
by the processes during post-translational protein modi-
fication (among others proteolytic treatment, hydroxyla-
tion, glycosylation, phosphorylation, ubiquitination, and 
polyribosylation). During the aforementioned processes, 
various sugar moieties responsible for the formation of 
bonds within the protein molecule are attached to the 
polypeptide chains, formatting the appropriate spatial 
structure required for proper (expected) functioning. 
The appropriate spatial structure of antibodies deter-
mines the critical pharmacological properties of these 
proteins, such as antigen specificity, affinity to immune 
cells, half-life, or immunogenicity.
The potentially enormous number of variables 
(physical, chemical, and biological factors), even re-
sulting from subtle modifications of functions of cells 
cultivated in bioreactors, can significantly alter the 
characteristics of the biological drug. Accordingly, 
manufacturing a biological drug requires very sophis-
ticated control and validation methods to ensure the 
expected pharmacological activity of the final product. 
The ideal situation is therefore the production of a bio-
logical drug in specific and unchangeable conditions, 
allowing in the long term to obtain exactly the same 
final product. However, taking into account the fact 
that biological drugs are formed in living cells whose 
functions depend on a huge number of variables (e.g. 
cell age, medium composition, ambient temperature, 
atmospheric pressure, electromagnetic radiation), it is 
known that the features of biological drugs produced 
by a single manufacturer could change over time, and 
the same biological drugs from different factories of 
the same manufacturer may have small differences. For 
example, due to possible minor differences between the 
trastuzumab preparations produced in Europe and the 
USA, some clinical trials compared the biosimilar with 
trastuzumab-US and trastuzumab-EU, simultaneously. 
Unlike generic drugs, in the case of biosimilars it 
is not enough to show that the drug is identical to the 
original chemical structure, e.g. the same amino acid 
sequence of the polypeptide chains. As already men-
tioned above, in the case of biological drugs an identical 
chemical structure does not necessarily mean the same 
spatial structure and identical biological effect, and 
thus the same antitumor potential and safety profile. In 
the case of biosimilars it is necessary not only to prove 
unchangeable and optimal production conditions, but 
first and foremost, comparable clinical efficacy and 
safety should be demonstrated in clinical trials. For this 
261
Piotr J. Wysocki et al., PSCO position statement on the urgent need of introduction of national standards for utilization of biologic drugs
Table 1. A summary of guidelines for use of biologics drugs in EU countries 
Biosimilar drugs are not generic drugs
Different biological drugs with the same international name cannot be considered fully interchangeable, and the consequences of 
uncontrolled change are not always predictable
No limitation in the choice of a biological drug (reference or biosimilar) at therapy initiation
Due to safety aspects and monitoring of adverse events, it is not recommended that biological drugs are replaced during treatment 
without medical justification
It is advisable to use trade names of biological drugs on medical orders
Possible change of biological drugs should be based on a physician’s decision
In some countries, official lists of “convertible” drugs are being developed, which can be subject to automatic substitution. 
Medications from this list must meet additional stringent replacement requirements. Other medicines, not listed, can only be 
changed based on a physician’s decision
reason, the introduction of biosimilars into the market 
is a far more complicated, time-consuming, and costly 
process compared to generic drugs.
Medical hazards associated  
with biosimilars
Regulatory agencies giving marketing authorisation 
of biosimilars are considering different aspects related to 
their introduction into clinical practice. Above all, they 
recommend long-term observation of patients for de-
layed and atypical side effects, which in the long term may 
potentially be revealed and have a different character 
than in the case of the original medicine. Each biological 
drug, both reference and biosimilar, is subject to special 
post-marketing safety surveillance (black triangle dis-
played in package leaflet). Due to inevitable differences 
in spatial structure of proteins and, consequently, the 
possible minor biological differences between particular 
biosimilars and original drugs, automatic replacement of 
biological drugs during therapy is not allowed (both from 
the original drug to biosimilar and vice versa). Lack of 
possibility of automatic replacement of the correspond-
ing biological drugs is primarily associated with safety 
aspects and the requirement of close monitoring and 
reporting of adverse reactions, which is one of the basic 
principles of systemic treatment in the era of biosimilar 
medicines. After achieving relatively unrestricted access 
to biosimilars in clinical practice the greatest challenges 
will be related to the issue of interchangeable use of 
biological drugs that are potentially the same molecule. 
Legal conditions in the European Union
EU legislation does not regulate the interchange-
ability of biological drugs. Regulatory agencies (e.g. 
the European Medicines Agency, EMA) evaluate 
biosimilars only for registration purposes, and this does 
not include recommendations for their interchangeable 
use with a reference drug or other biosimilar. General 
EMA recommendations for possible replacement of 
biological drugs indicate a key role for a physician or 
pharmacist; however, EU legislation delegates the rules 
of interchangeability of biological drugs to particular 
EU Member States.
Up to now, no EU Member State has explicitly 
agreed to automatic exchange of biological products 
from different manufacturers. Guidelines on the use of 
biological drugs have been developed in many countries 
in the world, including the majority of European Union 
countries (UK, France, Belgium, Finland, Slovenia, 
Croatia, Ireland, Italy, Luxembourg, Sweden, Spain, 
and the Netherlands) as well as in Switzerland and the 
USA (Tab. 1).
Polish regulations and substitution  
of biological drugs in clinical practice
No provision of Polish law requires automatic sub-
stitution of biological medicines. There are only two 
provisions directly related to biological drugs — the first 
concerns establishing specific requirements for market-
ing authorisation of biosimilars (Article 15 sec. 7 of the 
Pharmaceutical Law), while the second is applied to 
reporting of adverse reactions to medicinal products. In 
the case of biological drugs, providing a trade name of 
the drug and serial number is mandatory (Article 36h 
sec. 2 of the Pharmaceutical Law). Biological drugs are 
not in any way distinguished by the reimbursement law. 
In turn, the definitions of analogues contained in the 
Pharmaceutical Law and the Reimbursement Law do not 
take into account the specificity of biosimilars. As a con-
sequence, the application of the Public Procurement Law, 
which points to the need for equal treatment of all drugs 
with the same international name, hinders ring-fencing 
the packets for delivery of biological drugs for treatment 
continuation during tendering procedures. This results 
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in a situation where the healthcare provider is unable to 
provide a specific drug for continuation of therapy, even 
when all clinical data are against the drug’s replacement 
(not to mention multiple changes).
The presented interpretation of regulations may, as 
a consequence, force the conversion of biological drugs 
used in therapy not due to medical indications, but due 
to the availability of only one specific preparation in the 
pharmacy of the medical entity. In such a situation, the 
decision to replace a biological drug is only a result of 
a tender procedure, not a medically justified physician’s 
decision. As a result of the aforementioned actions, both 
the infringement of the patient’s rights and the conflict 
with basic principles of physician and healthcare pro-
vider responsibility can be claimed. 
The patient has the right to receive healthcare ser-
vices according to current medical knowledge (Article 
6 sec. 1 of the Patient Rights Act and the Patient Rights 
Ombudsman), as well as to provide consent to the given 
healthcare service and obtain information on available 
treatment methods, along with information about pos-
sible complications (Article 15 and following of this 
Act). Uncontrolled drug replacement during therapy, 
which in the case of biological drugs may have certain 
negative health consequences, is undoubtedly a violation 
of those patient’s rights. 
Legal threats to physician
According to Article 4 of the Act on doctors’ and 
dentists’ professions, the physician is required to practice, 
as indicated by current medical knowledge, the methods 
and means of prevention, diagnosis, and treatment of 
diseases available to him/her, in accordance with profes-
sional ethics and with due diligence. So, if, in spite of the 
lack of unambiguous clinical indications, the physician 
replaces one biological drug with another due to, for ex-
ample, unavailability of the previously used pharmaceu-
tical (purchase under the tender of another medicine), 
it is, in the eyes of the law, inconsistent with current 
medical knowledge. No provision excludes civil liability 
of a physician in this respect, and allowing medically 
unjustified exchange of biological drugs during therapy 
may have legal consequences in relation to the physician. 
Legal threats to the healthcare provider
The healthcare provider is potentially liable not only 
as a so-called substitute for culpable damage caused by 
physicians and medical staff employed by him/her (Article 
430 and Article 474 of the Civil Code), but also so-called 
organisational blame. This fault consists of the inadequate 
organisation of a medicinal entity, including limiting the 
physician’s choice of medicines or medical equipment. 
Inability to provide a drug for therapy continuation in 
clinically justified cases can therefore result in the pro-
vider’s liability for so-called organisational blame.
Legal threats to the State Treasury
The potential liability of the State Treasury, pursuant 
to art. 414 § 1 of the Civil Code, should also be taken into 
account. Claims in this regard may be brought by both the 
injured patient and the healthcare provider. In the case of 
the patient, this may include, for example, the suspicion 
that therapy failure or side effects leading to treatment 
discontinuation were a consequence of forcing an unjusti-
fied replacement of a biological drug to which the patient 
did not consent. On the other hand, in the case of the 
healthcare provider, this may result, for example, from the 
provider’s obligation to make a court judgment to remedy 
the injury caused by the replacement of a biological drug 
(e.g. due to the unavailability of a previously used drug).
The postulate to develop guidelines 
defining the principles of substitution  
of biological drugs 
With a view to the aforementioned threats, it is neces-
sary for the Polish State to establish clear rules for the 
substitution of biological drugs, with particular emphasis 
on oncological therapies. At this stage, it seems that there 
would be no need for changes at the legislative level, but 
only an official interpretation of the currently applicable 
statutory regulations regarding the conversion of biologi-
cal drugs, as is many European Union countries. 
The General Board of Polish Society of Clinical 
Oncology believes that the Ministry of Health, in coope-
ration with the President of the Office for Registration 
of Medicinal Products, Medical Devices, and Biocidal 
Products, and relevant experts, should develop and pub-
lish an official position on the use of biological drugs in 
Poland, together with a listing of biological drugs that 
are subject to automatic substitution. 
The mentioned position, recognised as general 
guidelines, should define standards for treatment with 
use of biological drugs, providing the necessary guidance 
to physicians, pharmacists, healthcare providers, payers, 
and all participants in the tendering procedures. Such 
guidelines would ensure healthcare providers with 
a sense of predictability of the purchasing policy and 
payer behaviour as regards settlement of drug services 
with the use of biological drugs. 
In the absence of unambiguous guidelines regard-
ing the use of biological drugs in Poland at the time 
of introduction into the market of biosimilars with 
antineoplastic activity, the Polish Society of Clinical 
Oncology draws attention to a number of health and 
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legal threats. The authors of the presented position 
express their hope that, as in other EU countries, clear 
standards of use of biological drugs will be urgently 
developed in Poland, which would allow numerous 
potential problems for patients, healthcare providers, 
and payers alike to be avoided. 
Summary of the position of the Polish 
Society of Clinical Oncology  
on biological drugs 
 — The need to develop clear rules for the use of original 
and biosimilar biological drugs.
 — The need to define and continuously update a list of 
medicines that can be automatically replaced.
 — The need to introduce in tender procedures the 
possibility of purchasing biological drugs for con-
tinuing treatment.
 — The need of use of trade and international names in 
medical documentation every time that a biological 
drug is used. 
 — The need to include in medical documentation all 
relevant information on the conversion of a biolo-
gical drug (the name of both medicines, the date of 
change, and information about the patient’s consent 
to such a change) in the case of drugs that are not 
eligible for automatic conversion.
